Lilly's lung cancer drug hits main goal in late-stage trial

08/14/2013 | Reuters · Pharmaceutical Business Review Online

Eli Lilly and Co.'s experimental drug necitumumab, or IMC-11F8, in combination with gemcitabine and cisplatin, met the primary goal of a Phase III trial by improving overall survival in patients with stage 4 squamous nonsmall-cell lung cancer compared with chemotherapy alone. The firm plans to submit the drug for FDA approval next year as a first-line therapy for squamous lung cancer. If approved, necitumumab would be the first biologic therapy for the condition.

View Full Article in:

Reuters · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ